Antigen Human Articles & Analysis
13 news found
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. ...
The Product Manager of the Long-Read Sequencing Division announced the launch of the Human Leukocyte Antigen (HLA) Typing service to support high-resolution HLA typing in a rapid and cost-efficient manner. ...
Bria-Pros is a novel off-the-shelf personalized immunotherapy for prostate cancer. It includes multiple Human leukocyte antigen (HLA)-specific immunotherapy cell lines that will be administered to patients based on each patient’s HLA type. ...
” First Quarter Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human placental CD34+ cells. ...
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor growth inhibition ...
” Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human placental CD34+ cells. ...
These high quality products include a range of antigen products, normal human serum, disease state plasma, standards, positive control materials, and reagents for diagnostic tests such as buffers, catalysts, cofactors, blockers, substrates, stabilizers agents and solvents. ...
(Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids ...
(Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
ASHI 2021 -- At the annual meeting for the American Society for Histocompatibility and Immunogenetics (ASHI) this week, Thermo Fisher Scientific announced two new additions to its transplant diagnostics portfolio. These new products will enable transplant laboratories to better characterize samples and bring speed and confidence to the transplant laboratory. More than 100,000 adults are now on a ...
To do this, they use their T-cell receptors (TCRs) to scan the surface of other cells for foreign antigens presented on Human Leukocyte Antigen (HLA) complexes. Cancer cells can be recognized by mutated or viral antigens expressed only in the tumor, or self-antigens normally expressed during embryonic development ...